Evidence map›Paper›PMID 39060928›Full record

ArticleMolecular medicine (Cambridge, Mass.)2024

Transcription factor 7 like 2 promotes metastasis in hepatocellular carcinoma via NEDD9-mediated activation of AKT/mTOR signaling pathway.

Linsong Tang, Shengjun Xu, Rongli Wei, Guanghan Fan, Junbin Zhou, Xuyong Wei, Xiao Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Linsong Tang *Department of Urology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Shengjun Xu *Institute of Translational Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Rongli WeiDepartment of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Guanghan FanDepartment of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Junbin ZhouDepartment of Hepatobiliary and Pancreatic Surgery, Lishui People's Hospital, Lishui, Zhejiang, China.
Xuyong WeiDepartment of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Xiao XuInstitute of Translational Medicine, Zhejiang University, Hangzhou, Zhejiang, China. zjxu@zju.edu.cn.ORCID 0000-0002-2761-2811

Funding

China Postdoctoral Science Foundation 2022M722764National Key Research and Development Program of China 2021YFA1100500The Major Research Plan of the National Natural Science Foundation of China 92159202Young Program of National Natural Science Funds 82200726
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is one of the most common malignant tumors of the digestive system, and the exact mechanism of HCC is still unclear. Transcription factor 7 like 2 (TCF7L2) plays a pivotal role in cell proliferation and stemness maintenance. However, the exact mechanism of TCF7L2 in HCC remains unclear.

methodsClinical samples and public databases were used to analyze the expression and prognosis of TCF7L2 in HCC. The function of TCF7L2 in HCC was studied in vitro and in vivo. ChIP and luciferase assays were used to explore the molecular mechanism of TCF7L2. The relationship between TCF7L2 and NEDD9 was verified in HCC clinical samples by tissue microarrays.

resultsThe expression of TCF7L2 was upregulated in HCC, and high expression of TCF7L2 was associated with poor prognosis of HCC patients. Overexpression of TCF7L2 promoted the metastasis of HCC in vitro and in vivo, while Knockdown of TCF7L2 showed the opposite effect. Mechanically, TCF7L2 activated neural precursor cell expressed developmentally downregulated protein 9 (NEDD9) transcription by binding to the -1522/-1509 site of the NEDD9 promoter region, thereby increasing the phosphorylation levels of AKT and mTOR. The combination of TCF7L2 and NEDD9 could distinguish the survival of HCC patients.

conclusionsThis study demonstrated that TCF7L2 promotes HCC metastasis by activating AKT/mTOR pathway in a NEDD9-dependent manner, suggesting that potential of TCF7L2 and NEDD9 as prognostic markers and therapeutic targets for HCC.

Indexed as

Adaptor Proteins, Signal TransducingCarcinoma, HepatocellularGene Expression Regulation, NeoplasticLiver NeoplasmsProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesTranscription Factor 7-Like 2 ProteinAnimalsCell Line, TumorCell ProliferationFemaleHumansMaleMiceMice, NudeAdaptor Proteins, Signal TransducingMTOR protein, humanNEDD9 protein, humanPhosphoproteinsProto-Oncogene Proteins c-aktTCF7L2 protein, humanTOR Serine-Threonine KinasesTranscription Factor 7-Like 2 ProteinAKT/mTOR pathwayHepatocellular carcinomaNEDD9TCF7L2Tumor metastasis

Identifiers

PMID39060928
PMCPMC11282612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.